STAT+: STAT+ Conversations: An update from STAT’s Pharmalot
Editors note: A livestream of the conversation will be embedded below at 1 p.m. ET….
Category: drug pricing
STAT+: Amgen’s KRAS cancer drug had a bad week, but worry about pricing, not safety
Investors do not like surprises with negative overtones, so they reacted badly when Amgen announced…
.jpg)
STAT+: Pharmalittle: Wyden goes back to the drawing board on drug pricing; Emergent undergoes an executive shake-up
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Top Senate Democrat heads back to drawing board on drug pricing
WASHINGTON — A powerful Democratic committee chair is starting to work on a new drug…
Listen: Biden’s punt on drug prices, Russia’s vaccine controversy, & the importance of tiny plastic cones
Does President Biden really care about drug prices? Is Sputnik V falling out of orbit?…
STAT+: Did someone say patent thicket? AbbVie CEO to testify before Congress about drug pricing tactics
As part of its probe into pharmaceutical industry pricing tactics, a Congressional committee next month…
Biden is set to ask for drug pricing reform this year. But it’s an empty call
WASHINGTON — President Biden is set to tell Congress tonight to let Medicare negotiate drug…
STAT+: Americans paid two to four times as much for some drugs as in three other countries
Amid national angst over the cost of prescription drugs, a new analysis finds that U.S….
Opinion: H.R. 3’s international reference pricing misses the mark
The White House and Congress have declared that reining in Medicare prescription drug costs to…
STAT+: Will India issue sidestep patents on a pair of pricey — but lifesaving — TB drugs?
A widely anticipated court hearing will be held in India on Wednesday over the cost…
STAT+: Drug pricing déjà vu: Now it’s Democrats struggling to unite on the issue
WASHINGTON — It’s the eve of a major speech by the president, and it’s anyone’s…
STAT+: Thanks to its Covid-19 response, pharma’s reputation among patient groups is climbing
Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe…
STAT+: Down and out Down Under? Bristol Myers fights an ‘unreasonable’ Australian law over patents
Two big drug makers are challenging a provision in Australian patent law that they argue…
STAT+: The price of a Vertex cystic fibrosis treatment stirs anger in Australia
The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals (VRTX)…
STAT+: ‘There are no alternatives’: As Pfizer discontinues an old glaucoma drug, a small group of patients struggles to cope
Next month, an eye drop that Carol Vaghar has taken for the past few years…
STAT+: Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support
WASHINGTON — At least one Democratic lawmaker is openly pushing President Biden to include drug…
STAT+: Hints emerge about a key Senate committee’s plans for health care
WASHINGTON — A Senate hearing Thursday provided one of the clearest roadmaps to date for…
STAT+: A U.S. appeals court upholds the FTC view of controversial pay-to-delay settlements
In what is being called a win for consumers, a U.S. appeals court upheld a…
STAT+: PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform
WASHINGTON — Steve Ubl, who leads the drug industry lobbying powerhouse PhRMA, has a bold…
STAT+: Europe tries to lower drug prices with small doses of transparency
For countries in Europe, negotiating a deal with a pharma company over drug prices is…
STAT+: Federal agency says pharma should pay higher Medicaid rebates if certain trials aren’t finished on time
In a bid to lower prescription drug costs, a federal agency is recommending pharmaceutical companies…
STAT+: Brazilian judge temporarily suspends pharmaceutical patent extensions amid push to lower drug costs
A Brazilian Supreme Court judge suspended extensions for pharmaceutical patents in the country, and although…
STAT+: A controversial court case in Brazil will tackle pharma ‘monopolies’ and access to drugs
After years of anticipation, the Brazilian Supreme Court is holding a hearing this week on…
STAT+: California once again delays launch of a closely watched prescription drug purchasing program
For the second time this year, California officials have delayed a much-ballyhooed effort to start…
STAT+: Lilly is a holdout among companies that agree to disclose when executive pay is clawed back
A coalition of institutional investors is pushing Eli Lilly to adopt a policy to disclose…
STAT+: Bristol Myers agrees to pay $75 million to settle allegations of underpaying Medicaid rebates
After years of litigation, Bristol-Myers Squibb (BMY) agreed to pay $75 million, plus interest, to…
STAT+: Most U.S. universities get an ‘F’ on ensuring access to drugs they discover
Despite large amounts of taxpayer funding, dozens of the largest U.S. universities failed to commit…
STAT+: Here are the drug pricing policy options Democrats could use to pay for their next big legislative push
WASHINGTON — Democrats in Congress are already gearing up for their next big legislative push,…
STAT+: Congressional lawmakers urge FTC to investigate insulin makers over their pricing
In the latest flare up over the cost of insulin, several Congressional lawmakers want the…
STAT+: Canada says drug spending keeps rising due to increasingly expensive specialty meds
As Canadians brace for new rules to address prescription drug spending, a government report found…
STAT+: Pharmalittle: AstraZeneca may have used ‘outdated’ info about its Covid-19 shot; Democrats eye drug-pricing measures
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharma wins a round in a battle with HHS over a drug discount program for hospitals
In a victory for the pharmaceutical industry, a federal judge temporarily blocked the federal government…
STAT+: Washington may become the second state to distribute its own generic drugs
A bill moving through the Washington legislature may make the state only the second in…
STAT+: Xavier Becerra’s 4 most urgent challenges as Biden’s soon-to-be HHS secretary
WASHINGTON — Xavier Becerra has survived the worst of a tense confirmation battle to become…
STAT+: Once again, the viability of the U.S. biosimilar market is thrown into question
Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care…
STAT+: Insulin makers win a significant round in Minnesota lawsuit accusing them of racketeering
In a setback to efforts to control insulin prices, a U.S. court judge tossed key…
STAT+: Insulin makers win a significant round in Minnesota lawsuit accusing them of racketeering
In a setback to efforts to control insulin prices, a U.S. court judge tossed key…
Opinion: Choosing the right director for the U.S. Patent and Trademark Office can help lower drug prices
As the Biden administration fills key Cabinet positions, its attention must turn to other critical…
Opinion: Reining in drug patents isn’t a silver bullet against high drug prices
One of the top orders of business for the Biden administration is curbing drug prices….
STAT+: Medicare spending on neurology drugs jumped, while number of claims barely budged
During a recent five-year period, Medicare spending on hundreds of medicines to treat various neurologic…
STAT+: Biden’s silence on an FDA nominee underscores how tough it is to fill that job
WASHINGTON — Nearly everyone here expected President Biden to move with record speed to nominate…
STAT+: Lawmakers rail against huge tax breaks drug wholesalers get from opioid settlement
Three congressional lawmakers are examining the extent to which pharmaceutical wholesalers and a leading drug…
STAT+: European Commission probes Teva for allegedly using patents to thwart competition
In its latest bid to ensure competition among drug makers, the European Commission has opened…
STAT+: Health care industry scores lobbying wins in Senate on drug pricing, provider funds, insurance subsidies
WASHINGTON — Health care industry lobbying groups are poised to score big wins in the…
STAT+: A nascent state effort would tax drug makers for not providing clinical evidence for price hikes
In a bid to control the cost of medicines, lawmakers in two states — Hawaii…
.jpg)
STAT+: New Mexico attorney general accuses Gilead of blocking competition to its HIV medicines
The New Mexico attorney general has filed a lawsuit against Gilead Sciences (GILD) and two…
STAT+: The vial is not half empty: New report lays out ways to address the issue of discarded drugs
File this under ‘Waste not, want not.’ In response to the cost of medicines, a…
STAT+: Republicans’ surprising Becerra attack: He’s not sympathetic enough to pharma
WASHINGTON — Republican senators on Tuesday blasted President Biden’s health secretary nominee using an unexpected…
STAT+: States still can’t import drugs from Canada. Now, many are seeking to import Canadian prices
WASHINGTON — For years, former President Trump threatened to use foreign prices as a cap…
Once again, senators want GAO to probe the role of PBMs in prescription drug pricing
In a bid to contain prescription drug prices, a pair of U.S. senators is re-introducing…